Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases
Authors
Keywords
-
Journal
Expert Review of Clinical Immunology
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2019-07-19
DOI
10.1080/1744666x.2019.1646127
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety of Biologic Therapy in Older Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis
- (2019) Nienke Z. Borren et al. Clinical Gastroenterology and Hepatology
- Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis
- (2019) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
- (2018) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease
- (2018) James D Lewis et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry
- (2018) Geert D’Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study
- (2018) Nabeel Khan et al. Clinical Gastroenterology and Hepatology
- Increased Risk of Herpes Zoster Infection in Patients With Inflammatory Bowel Diseases in Korea
- (2018) Kiju Chang et al. Clinical Gastroenterology and Hepatology
- Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases
- (2018) Nghia H. Nguyen et al. Clinical Gastroenterology and Hepatology
- 277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis
- (2018) Dana J. Lukin et al. GASTROENTEROLOGY
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases
- (2018) Julien Kirchgesner et al. GASTROENTEROLOGY
- What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
- (2018) Timothy Card et al. INFLAMMATORY BOWEL DISEASES
- Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
- (2018) Gary R Lichtenstein et al. INFLAMMATORY BOWEL DISEASES
- Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2018) Zenas Z.N. Yiu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
- (2018) Joseph Meserve et al. Clinical Gastroenterology and Hepatology
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
- (2017) Paula Dávila-Seijo et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry
- (2017) David Fiorentino et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab
- (2016) Mark T Osterman et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
- (2016) Stefanos Bonovas et al. Clinical Gastroenterology and Hepatology
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study
- (2016) Livia Biancone et al. Journal of Crohns & Colitis
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between tumour necrosis factor- inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
- (2015) N. Nyboe Andersen et al. BMJ-British Medical Journal
- Association between tumour necrosis factor- inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
- (2015) N. Nyboe Andersen et al. BMJ-British Medical Journal
- Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study
- (2014) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease
- (2014) Nynne Nyboe Andersen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
- (2013) R. Panaccione et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD
- (2013) Laura E Targownik et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis
- (2013) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
- (2013) Mark T. Osterman et al. GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
- (2013) Ole Haagen Nielsen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Melanoma in Patients Who Receive Thiopurines for Inflammatory Bowel Disease Is Not Increased
- (2012) Laurent Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
- (2012) Millie D. Long et al. GASTROENTEROLOGY
- Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies
- (2011) Walter Reinisch et al. INFLAMMATORY BOWEL DISEASES
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
- (2011) Carlos G. Grijalva et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inflammatory Bowel Disease
- (2009) Clara Abraham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
- (2008) Murat Toruner et al. GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started